IONS PE Ratio & Valuation, Is IONS Overvalued

Historical Valuation

Ionis Pharmaceuticals Inc (IONS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 16.79 is considered Overvalued compared with the five-year average of -21.33. The fair price of Ionis Pharmaceuticals Inc (IONS) is between 33.80 to 50.06 according to relative valuation method. Compared to the current price of 75.66 USD , Ionis Pharmaceuticals Inc By Overvalued By 51.15%.

Relative Value

Fair Zone

33.80-50.06

Current Price：75.66

51.15%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Ionis Pharmaceuticals Inc (IONS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Ionis Pharmaceuticals Inc (IONS) has a current Price-to-Book (P/B) ratio of 20.77. Compared to its 3-year average P/B ratio of 15.78, the current P/B ratio is approximately 31.62% higher. Relative to its 5-year average P/B ratio of 12.75, the current P/B ratio is about 62.91% higher. Ionis Pharmaceuticals Inc (IONS) has a Forward Free Cash Flow (FCF) yield of approximately -2.35%. Compared to its 3-year average FCF yield of -6.46%, the current FCF yield is approximately -63.69% lower. Relative to its 5-year average FCF yield of -3.92%, the current FCF yield is about -40.12% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for IONS competitors is 7.19, providing a benchmark for relative valuation. Ionis Pharmaceuticals Inc Corp (IONS.O) exhibits a P/S ratio of 16.79, which is 133.45% above the industry average. Given its robust revenue growth of -10.26%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of IONS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of IONS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is IONS currently overvalued or undervalued?

Ionis Pharmaceuticals Inc (IONS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 16.79 is considered Overvalued compared with the five-year average of -21.33. The fair price of Ionis Pharmaceuticals Inc (IONS) is between 33.80 to 50.06 according to relative valuation method. Compared to the current price of 75.66 USD, Ionis Pharmaceuticals Inc is Overvalued By 51.15%.

What is Ionis Pharmaceuticals Inc (IONS) fair value?

IONS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Ionis Pharmaceuticals Inc (IONS) is between 33.80 to 50.06 according to relative valuation method.

How does IONS's valuation metrics compare to the industry average?

The average P/S ratio for IONS's competitors is 7.19, providing a benchmark for relative valuation. Ionis Pharmaceuticals Inc Corp (IONS) exhibits a P/S ratio of 16.79, which is 133.45% above the industry average. Given its robust revenue growth of -10.26%, this premium appears unsustainable.

What is the current P/B ratio for Ionis Pharmaceuticals Inc (IONS) as of Mar 11 2026?

As of Mar 11 2026, Ionis Pharmaceuticals Inc (IONS) has a P/B ratio of 20.77. This indicates that the market values IONS at 20.77 times its book value.

What is the current FCF Yield for Ionis Pharmaceuticals Inc (IONS) as of Mar 11 2026?

As of Mar 11 2026, Ionis Pharmaceuticals Inc (IONS) has a FCF Yield of -2.35%. This means that for every dollar of Ionis Pharmaceuticals Inc's market capitalization, the company generates -2.35 cents in free cash flow.

What is the current Forward P/E ratio for Ionis Pharmaceuticals Inc (IONS) as of Mar 11 2026?

As of Mar 11 2026, Ionis Pharmaceuticals Inc (IONS) has a Forward P/E ratio of -29.54. This means the market is willing to pay $-29.54 for every dollar of Ionis Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Ionis Pharmaceuticals Inc (IONS) as of Mar 11 2026?

As of Mar 11 2026, Ionis Pharmaceuticals Inc (IONS) has a Forward P/S ratio of 16.79. This means the market is valuing IONS at $16.79 for every dollar of expected revenue over the next 12 months.

IONS Valuation